Investment In HIV/AIDS Vaccine R&D Must Be Scaled Up

Global Health Technology Coalition’s “Breakthroughs”: Four reasons now is the time to ramp up investment in HIV/AIDS vaccine R&D
Kat Kelley, GHTC’s senior program assistant, reports from a recent briefing on Capitol Hill that “convened leaders in the field to discuss the state of HIV/AIDS vaccine research and development (R&D). … [T]he discussion illustrated four key reasons why now is the time to ramp up — rather than scale down — investment in HIV/AIDS vaccine R&D. … We are closer than ever to developing an HIV/AIDS vaccine … We cannot eradicate HIV/AIDS without a vaccine … Investments in HIV/AIDS vaccine R&D are producing broader impacts on global health … A vaccine for HIV/AIDS would have enormous financial benefits” (5/22).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.